Showing 5941-5950 of 9111 results for "".
- Study: Dupilumab Shows Long-Term Disease Control in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/study-dupilumab-shows-long-term-disease-control-in-pediatric-atopic-dermatitis/2487681/Children and adolescents with moderate-to-severe atopic dermatitis (AD) maintained improvements in disease signs and symptoms during 1 year of dupilumab treatment, according to a post hoc analysis of the ongoing phase 3 LIBERTY AD PED-OLE open-label extension study
- FDA Grants SKYRIZI Approval to Children With Plaque Psoriasis and PsAhttps://practicaldermatology.com/news/fda-expands-skyrizi-approval-to-include-children-with-plaque-psoriasis-and-psoriatic-arthritis/2487657/The FDA has expanded the indication for SKYRIZI® (risankizumab-rzaa) to include children aged 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to an announcement from AbbVie.
- Study Shows Racial Differences in Pseudofolliculitis Barbae Complications, Treatment Timinghttps://practicaldermatology.com/news/racial-differences-in-pfb-complications-treatment-timing-highlight-care-gaps/2487632/A multicenter retrospective cohort study published as a Letter to the Editor in the Journal of Drugs in Dermatology found that Black patients with pseudofolliculitis barbae (PFB) experienced significantly higher rates of post-inflammatory hyperpigmentation (PIH) and hypertrophic scarring
- Study: Off-Label Dosing Shows Limited Benefit for Brodalumab, Bimekizumab in Psoriasishttps://practicaldermatology.com/news/study-off-label-dosing-shows-limited-benefit-for-brodalumab-bimekizumab-in-psoriasis/2487623/A systematic review published in Archives of Dermatological Research suggested deviations from approved dosing schedules offered limited clinical advantage in patients with plaque psoriasis, while maintaining similar safety. Investigators reviewed randomized controlled trials and
- Letter Questions Strength of Evidence Linking Hair Relaxers to Uterine Cancerhttps://practicaldermatology.com/news/letter-questions-strength-of-evidence-linking-hair-relaxers-to-uterine-cancer/2487618/A recently published Letter to the Editor in the Journal of Drugs in Dermatology urged clinicians to interpret the growing body of research examining chemical hair relaxers and uterine cancer with caution, arguing that important methodological limitations prevent current evidence from es
- ESCD 2026: New Data Show Ongoing Burden of Chronic Hand Eczemahttps://practicaldermatology.com/news/escd-2026-new-data-on-chronic-hand-eczema-burden-and-unmet-needs/2487581/LEO Pharma will present new data at the European Society of Contact Dermatitis (ESCD) Congress 2026 in Copenhagen highlighting the significant burden chronic hand eczema (CHE) continues to place on patients across different stages of life, according to a press release from the manufacturer. The p
- Emblation Partners With DermLite to Expand Access to Dermoscopy for Podiatristshttps://practicaldermatology.com/news/emblation-partners-with-dermlite-to-expand-access-to-dermoscopy-for-podiatrists/2487590/Emblation has announced a new collaboration with DermLite that will make the DermLite DL1 dermatoscope available through the Swift store, expanding access to dermoscopy tools for podiatrists using the company's Swift microwave therapy platform.
- Skin Cancer Champions Earns Two Digital Health Awards for Patient Education and Community Engagementhttps://practicaldermatology.com/news/skin-cancer-champions-earns-two-digital-health-awards-for-patient-education-and-community-engagement/2487580/Skin Cancer Champions, an online community dedicated to supporting patients and caregivers affected by non-melanoma skin cancers, has received two Bronze Awards in the Spring 2026 Digital Health Awards, presented by the Health Information Resource Center (HIRC). The awards recognize the or
- Takeda Reports Positive Phase 3 Results for Oral TYK2 Inhibitor Zasocitinibhttps://practicaldermatology.com/news/takeda-reports-positive-phase-3-results-for-oral-tyk2-inhibitor-zasocitinib/2487546/Takeda announced positive topline results from the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004) trial, a head-to-head study evaluating the investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) against deucravacitinib in adults with moderate-to-severe plaque psoriasis.
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://practicaldermatology.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi